Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus LIDEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus LIDEX.
ARAZLO vs LIDEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Glucocorticoid receptor agonist; inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis; suppresses inflammatory cytokines and immune cell migration.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Terminal elimination half-life: 28-36 hours. Clinical context: Steady-state achieved in ~5-7 days; once-daily dosing maintains therapeutic levels without accumulation in patients with normal renal function.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Renal (primarily as metabolites) ~ 95%; biliary/fecal ~5%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid